Thus, although TAAR1 agonists demonstrate antipsychotic-like efficacy in schizophrenia models, they are unlikely to cause extrapyramidal side effects (EPS, movement disorders), which are a well-known side effect of current antipsychotics. This evidence concerns the gene TAAR1 and schizophrenia.